apls stocktwits:Apellis Pharmaceuticals Inc (APLS) Stock Forecast
Apellis Pharmaceuticals Inc (APLS) Stock Forecast
Basedon16WallStreetanalystsoffering12monthpricetargetsforApellisPharmaceuticalsinthelast3months.Theaveragepricetargetis$71.40witha ...。其他文章還包含有:「APLSApellisPharmaceuticalsInc」、「ApellisPharmaceuticalsInc(APLS)Fundamental&...」、「ApellisPharmaceuticalsInc(APLS)News」、「Earnings」、「ApellisPharmaceuticals,Inc.(APLS)StockPrice」、「ApellisPharmaceuticals」、「APLS$APLSStockCharts,...
查看更多 離開網站APLS Apellis Pharmaceuticals Inc
https://stocktwits.com
APLS Apellis Pharmaceuticals Inc. 3,077. $37.62. $1.60. (4.44%). Today. Watchers, 3,077. 52-Wk Low, $29.79. 52-Wk High, $73.80. Market Cap, $4.58B.
Apellis Pharmaceuticals Inc (APLS) Fundamental & ...
https://stocktwits.com
Get all financial information for Apellis Pharmaceuticals Inc (APLS) including Market ... Stocktwits. Sentiment · News · Earnings. Content. Upgrade. Trending.
Apellis Pharmaceuticals Inc (APLS) News
https://stocktwits.com
Find Apellis Pharmaceuticals Inc (APLS) news, corporate events, press releases, latest company updates and headlines.
Earnings
https://stocktwits.com
Checkout Apellis Pharmaceuticals Inc (APLS) earnings results, EPS expectations and actual EPS values for both quarterly and annual periods.
Apellis Pharmaceuticals, Inc. (APLS) Stock Price
https://finance.yahoo.com
Find the latest Apellis Pharmaceuticals, Inc. (APLS) stock quote, history, news and other vital information to help you with your stock trading and ...
Apellis Pharmaceuticals
https://finance.yahoo.com
Find the latest Apellis Pharmaceuticals, Inc. (APLS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders ...
APLS $APLS Stock Charts, Analysis
https://www.stockconsultant.co
APLS, $APLS, Apellis Pharmaceuticals Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend ...
APLS Stock Soars 30% After Identifying Potential Culprit ...
https://www.investors.com
Shares of APLS stock rocketed Wednesday after Apellis identified the potential culprit behind inflammation following its drug, Syfovre.